MP-Azeflu Improves Quality of Life of Patients with Allergic Rhinitis: A Real-World Study

Ranny Van Weissenbruch, Ludger Klimek, Gabriella Galffy, Melanie Emmeluth, Arkady Koltun, Ferdinand Kopietz, Duc Tung Nguyen, Hans Christian Kuhl, Wolfgang Pohl, Glenis Scadding, David Price, Jaoquim Mullol

Research output: Contribution to conferenceAbstractpeer-review


Patients with poorly controlled allergic rhinitis (AR) experience nasal and ocular symptoms, and suffer from sleep disturbances, emotional problems, and activity impairment. In patients with more severe disease, AR is often associated with impaired quality of life (QOL). MP-AzeFlu (137 µg azelastine hydrochloride/50 µg fluticasone propionate intranasal spray) is safe and effective, but the impact on QOL among patients with AR requires further real-world investigation. The main objective of this observational study was to evaluate changes in patient sleep quality and trouble with daily work and social activities after ~14 days of treatment with MP-AzeFlu in routine clinical practice.
Original languageEnglish
Publication statusPublished - 6 Jun 2020
EventEAACI Digital Congress 2020 - Digital, London, United Kingdom
Duration: 6 Jun 20208 Jun 2020


ConferenceEAACI Digital Congress 2020
Country/TerritoryUnited Kingdom


Dive into the research topics of 'MP-Azeflu Improves Quality of Life of Patients with Allergic Rhinitis: A Real-World Study'. Together they form a unique fingerprint.

Cite this